Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01747629 · ClinicalTrials.gov registry record · Phase 3
Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics
A Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
NCT01747629 is a Phase 3 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 160 participants.
The verdict
NCT01747629, a Phase 3 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of Albuterol Spiromax® versus placebo in subjects with persistent asthma.
Interventions
- DRUG Placebo MDPI
- DRUG Albuterol MDPI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2012-12 |
| Est. Completion | 2013-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01747629
The ClinicalTrials.gov registry entry for NCT01747629 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo MDPI is the first listed.
NCT01747629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01747629 about?
NCT01747629 is a clinical study titled "Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics". The primary objective of this study is to evaluate the efficacy of Albuterol Spiromax® versus placebo in subjects with persistent asthma.
What is the current status of trial NCT01747629?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2012-12. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01747629?
The interventions under investigation include: Placebo MDPI (DRUG), Albuterol MDPI (DRUG).
Who is sponsoring clinical trial NCT01747629?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.